stockrow
Friday 6 November 2026
Export IOVA’s income statement to Excel — free account
Iovance Biotherapeutics, Inc.
IOVA Healthcare Biotechnology
Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024.
- Revenue
- +80.1%
- EPS
- +80.0%
- Free cash flow
- +89.7%
Quarter to September 2026, against a year earlier
7.99
0.25
+3.23%
Follow IOVA
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 6 | 4 | — |
+8 more TTM periods Free account |
| (29.11%) | (40.36%) | (47.51%) | (55.50%) | ||
| (23.26%) | (31.76%) | (37.40%) | (42.88%) | ||
ROIC |
(17.72%) | (42.96%) | (55.59%) | (62.77%) | |
Return on Tangible Assets |
(38.48%) | (59.22%) | (75.53%) | (89.79%) | |
Average Days of Receivables |
103.04 | 114.70 | 104.48 | 114.21 | |
Free Cash Flow per Share |
0.00 | (0.66) | (0.73) | (0.94) | |
Free Cash Flow |
(216.05) | (296.39) | (305.02) | (336.24) | |
Capital Expenditures |
(26.10) | (32.21) | (34.23) | (33.84) | |
| Other line items | |||||
Cash ROIC |
(26.59%) | (28.67%) | (29.47%) | (33.77%) | |
Accounts Receivable Turnover |
4.36 | 4.01 | 3.74 | 3.47 | |
Accounts Payable Turnover |
0.00 | 5.76 | 5.25 | 6.97 | |
Inventory Turnover |
0.00 | 3.18 | 2.79 | 3.36 | |
Average Days of Payables |
0.00 | 57.05 | 79.03 | 46.70 | |
Days of Inventory on Hand |
0.00 | 121.01 | 123.19 | 108.92 | |
Tax Rate |
(0.01) | (0.01) | 0.00 | (0.01) | |
Research and Development Expense of Revenue |
0.00% | 82.38% | 100.41% | 113.95% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 45.90% | 51.63% | 57.81% | |
Share Based Compensation of Revenue |
12.31% | 14.38% | 17.48% | 23.37% | |
Operating CF/Net income |
0.86 | 0.91 | 0.77 | 0.77 | |
Depreciation/Fixed assets |
0.00 | 0.30 | 0.30 | 0.31 | |
Capex/Depreciation |
0.00 | (0.82) | (0.86) | (0.84) | |
Revenue per Share |
0.00 | 0.72 | 0.68 | 0.74 | |
Operating CF per Share |
0.00 | (0.59) | (0.65) | (0.85) | |
Capex per Share |
0.00 | (0.07) | (0.08) | (0.09) | |
Capex to Sales |
0.07 | 0.10 | 0.12 | 0.13 |
Columns are period end dates · fundamentals updated 5 Nov 2026